Last reviewed · How we verify
ACP-104
ACP-104 is a selective histamine H3 receptor inverse agonist.
ACP-104 is a selective histamine H3 receptor inverse agonist. Used for Excessive daytime sleepiness in patients with narcolepsy or other conditions.
At a glance
| Generic name | ACP-104 |
|---|---|
| Sponsor | ACADIA Pharmaceuticals Inc. |
| Drug class | Histamine H3 receptor inverse agonist |
| Target | Histamine H3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By acting as an inverse agonist, ACP-104 decreases histamine signaling in the brain, which may help regulate sleep-wake cycles and improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or other conditions.
Approved indications
- Excessive daytime sleepiness in patients with narcolepsy or other conditions
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- ACP-104 in Acutely Psychotic Subjects With Schizophrenia (PHASE2)
- Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACP-104 CI brief — competitive landscape report
- ACP-104 updates RSS · CI watch RSS
- ACADIA Pharmaceuticals Inc. portfolio CI